> Google investors won't be able to invest in high-risk biotech startups if they aren't accredited. Everyday investors are only allowed to access weird investments through the left-field bets of big companies.

Only they can't do it that way, because if you buy a share of Alphabet, basically the entire value is from Google and even if one of the little left-field bets triples in value it would have only marginal impact on the overall share price.

Meanwhile if you did want to do such a thing, the better solution would be to have a fund with the sole purpose of investing in high-risk biotech startups, and then invest in a slew of them to better diversify the risk. Then let retail investors buy shares in that entity, which is all biotech instead of being a tiny sliver of biotech but really mostly Google.

Becoming an accredited investor doesn't take a lot of money... I would bet a good chunk of this site qualifies under the rules.